


Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Graphical abstract



Authors

Kate Childs, Christopher Davis, Mary Cannon, ..., Emma C. Thomson, Geoff Dusheiko, Kosh Agarwal

Correspondence

kate.childs@nhs.net
(K. Childs)

Lay summary

Direct-acting antiviral medications are able to cure hepatitis C in the majority of patients. The most common genotype of hepatitis C in Europe and the United States is genotype 1a or 1b and most clinical trials focused on these genotypes. We report that in a group of African patients, most of them had unusual (non-1a/1b) genotype 1 subtypes, and that the cure rate in these unusual genotypes was lower than in genotypes 1a and 1b.

Highlights

- Unusual genotypes (G1 non 1a/1b or G4 non 4a/4d) were common in African patients.
- 11 previously unclassified HCV subtypes were represented including novel G1p.
- Patients with unusual G1 subtypes had a lower SVR rate than any other genotype.
- Failures were driven by patients treated with a first generation NS5A inhibitor.
- The majority of unusual G1 subtypes had baseline NS5A resistance mutations.



Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Kate Childs^{1,*}, Christopher Davis², Mary Cannon¹, Sarah Montague¹, Ana Filipe², Lily Tong², Peter Simmonds³, Donald Smith^{3,4}, Emma C. Thomson², Geoff Dusheiko¹, Kosh Agarwal¹

¹Institute of Liver Studies, King's College Hospital Trust, United Kingdom; ²MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom; ³Nuffield Department of Medicine, University of Oxford, United Kingdom; ⁴ICTV Online (10th) Report, University of Edinburgh, United Kingdom

See Editorial, pages 1070–1072

Background & Aims: HCV subtypes which are unusual in Europe are more prevalent in the African region, but little is known of their response to direct-acting antivirals (DAAs). These include non-1a/1b/ non-subtypeable genotype 1 (G1) or non-4a/4d (G4). In this report we aimed to describe the genotype distribution and treatment outcome in a south London cohort of African patients.

Methods: We identified all patients born in Africa who attended our clinic from 2010–2018. Information on HCV genotype, treatment regimen and outcome were obtained. Non-subtypeable samples were analysed using Glasgow NimbleGen next-generation sequencing (NGS). Phylogenetic analysis was carried out by generating an uncorrected nucleotide p-distance tree from the complete coding regions of our sequences.

Results: Of 91 African patients, 47 (52%) were infected with an unusual subtype. Fourteen novel, as yet undesignated subtypes (G1*), were identified by NGS. Three individuals were infected with the same subtype, now designated as subtype 1p. Baseline sequences were available for 22 patients; 18/22 (82%) had baseline NS5A resistance-associated substitutions (RASs). Sustained virological response (SVR) was achieved in 56/63 (89%) overall, yet only in 21/28 (75%) of those with unusual G1 subtypes, with failure in 3/16 G1*, 1/2 G1p and 3/3 in G1l. Six treatment failures occurred with sofosbuvir/ledipasvir compared to 1 failure on a PI-based regimen. The SVR rate for all other genotypes and subtypes was 35/35 (100%).

Conclusions: Most individuals in an unselected cohort of African patients were infected with an unusual genotype, including novel subtype 1p. The SVR rate of those with unusual G1 subtypes was 75%, raising concern about expansion of DAAs across Africa. Depending on the regimen used, higher failure rates in African cohorts could jeopardise HCV elimination.

Lay summary: Direct-acting antiviral medications are able to cure hepatitis C in the majority of patients. The most common genotype of hepatitis C in Europe and the United States is genotype 1a or 1b and most clinical trials focused on these geno-

types. We report that in a group of African patients, most of them had unusual (non-1a/1b) genotype 1 subtypes, and that the cure rate in these unusual genotypes was lower than in genotypes 1a and 1b.

© 2019 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Direct-acting antiviral therapy (DAA) therapy has revolutionised hepatitis C (HCV) treatment. High cure rates with short courses of treatment make global eradication of HCV feasible; consequently, the World Health Organisation has promulgated a call for elimination of viral hepatitis as a public health threat by 2030.¹

With 11 million people infected, HCV has an estimated prevalence of 1% in the African region.¹ Despite this, there have been few clinical trials conducted in African cohorts and data is lacking on the prevalence, geographical distribution and treatment response of African sub-genotypes.^{2,3}

There are 8 known HCV genotypes which have been classified based on the analysis of HCV genetic sequences.⁴ Except for genotypes 5 and 8, each genotype is further divided into a number of subtypes. A genome-wide nucleotide sequence difference of 31–33% is considered sufficient to differentiate a genotype and a difference of 12–15% is sufficient to distinguish a sub-genotype (or subtype), although these boundaries are not strict and phylogeny is also considered.

Clinical trial and real-life data routinely report sustained virological response (SVR) rates in excess of 95% for genotype 1a, (G1a) 1b, 3 and 4. There are fewer data available on less prevalent genotypes such as 5 or 6, nor are unusual subtypes well represented. In an analysis of over 1,700 patients with genotype 1 HCV, who had been enrolled in clinical trials of NS5A inhibitors, less than 1% had subtypes of genotype 1 other than 1a or 1b.⁵ The available evidence suggests that other genotype 1 subtypes are common in Africa but less frequent in the industrialised countries where clinical trials have been centred.^{6,16} In this paper we refer to these as “unusual genotypes”. We choose this nomenclature for clarity as these genotypes are unusual in Europe, but not unusual in Africa, as we will discuss. However, there is a paucity of data as to whether the treatment

Keywords: Hepatitis C; Antiviral Therapy; Africa; Treatment Failures.
Received 3 May 2019; received in revised form 9 July 2019; accepted 26 July 2019;
available online 7 August 2019

* Corresponding author. Address: Institute of Liver Studies, King's College Hospital Trust, London, United Kingdom.

E-mail address: kate.childs@nhs.net (K. Childs).



Phylogenetic analysis

An uncorrected nucleotide p-distance tree was generated using MEGA 7.0 from the complete coding regions of our sequences after alignment using MAFFT with a reference set of subtypes, including unassigned genotype 1 sequences. Maximum likelihood phylogenetic analysis was carried out using RaxML and the best fit model (GTR+G+I).

Statistical analysis

Continuous variables were reported as median (interquartile range). Categorical univariate analysis was carried out using Chi Square and Fishers exact test. Analysis was performed using

SPSS Statistics v25. When performing multivariate analysis, the small numbers led to issues of separation in the data therefore bias-reduced penalized-likelihood logistic regression (Firth 1993) was used.¹⁰ This was implemented in the 'logistf' R package and penalized-likelihood ratio tests were used to assess significance.¹¹ Variables with a *p* value of <0.05 in univariate analysis were included in multivariate analysis.

Results

Sub-genotypes prevalent in African patients

The total number of patients with HCV seen at our centre between 2010 and 2018 was 2,211, of whom we identified 91 (4.1%) patients who were born in Africa, the majority from sub-Saharan Africa (Table 1). The ethnicity or country of birth of the whole HCV cohort are shown in Fig. 1. Amongst the African patients 20/91 (22%) patients were infected with genotype 1a or 1b, 35 (39%) patients had unusual African genotype 1 subtypes, including sub-genotypes 1e, 1g, 1h, 1l, and 23 patients had unassigned genotype 1. Five patients (5.6%) were infected with genotype 2; 3 (3.3%) were infected with genotype 3; 14 (15.6%) had genotype 4; 12 (13.1%) were infected with unusual subtypes of genotype type 4, including 4c, 4e, 4f, 4k, 4r; 2 patients had genotype 5 and 6 infection. The frequency of HCV genotypes of the whole cohort compared to the African group are shown in Fig. 2. Of the non-African patients, who were predominantly British born, but also included Asian, Caribbean and other European backgrounds, 38.7% were infected with genotype 1a, 15.2% with G1b, 30.4% with G3a and only 3.3% with unassigned G1.




Fig. 2. Distribution of HCV genotype amongst 91 African patients (white bars) compared to the rest of the HCV cohort (blue bars).




Fig. 3. HCV genotypes according to country of birth in African patients. (This figure appears in colour on the web.)

In the African cohort, HCV genotypes according to country of birth are shown in Table 1 and Fig. 3. Of the 23 unassigned genotype 1 samples that underwent NGS, 18 complete open reading frame sequences from 15 novel unassigned subtypes were identified. Formal HCV sub-genotype assignment and classification requires at least 3 epidemiologically unrelated isolates.⁴ We met this recognised criterion with samples from 3 individuals from Nigeria, shown on the p-distance tree as Patient (P)15, P17, and P38. Two of the patients were a married couple, however phylogenetic analysis indicated that they were infected with different variants of the same subtype. This novel subtype has been assigned as 1p. It should be noted that 1 of our patients who failed treatment with sofosbuvir and ledipasvir, P17, was infected with the newly identified genotype 1p.

Of our remaining unassigned 14 subtypes, 3 had pairs of unrelated sequences and the remainder only 1 unrelated sequence. We refer to these novel unclassified subtypes as G1*. These are shown on the phylogenetic tree in Fig. 4.

Treatment response

To date, 63 patients have completed DAA treatment and follow-up. Fifty-six of these patients have achieved an SVR, while 7 failed treatment, giving an overall SVR rate of 89%. As expected, response rates in genotypes 1a or 1b were uniformly high. Similarly, all patients infected with genotype 2, 3, 4 and 5 achieved an SVR. In those patients with unusual G1 and G4 African subtypes, treatment response according to genotype and choice of treatment regimen are shown in Table 2. An SVR was observed in only 21 of the 28 (75%) patients infected with unusual African genotype 1.

Five patients who failed initial treatment have thus far commenced retreatment: 3 of these patients have completed 16 weeks of glecaprevir and pibrentasvir, 2 of whom have achieved an SVR. One individual with cirrhosis and G1* HCV virus failed to achieve an SVR with 16 weeks of glecaprevir and pibrentasvir. Two other patients were retreated with sofosbuvir, velpatasvir and voxilaprevir and achieved an SVR.




Fig. 4. Phylogenetic analysis of HCV complete genome sequences. Our samples are in bold font and labelled by patient code and country of birth. Confirmed and previously reported unclassified reference sequences are shown in non-bold font. For patients who failed treatment, baseline and post treatment sequences are shown. P-distance corresponds to percentage of nucleotide positions at which sequence of interest differs from reference sequence and is measured horizontally. Novel subtype 1p is highlighted.

Table 2. HCV treatment outcomes according to genotypes in African patients.

Genotype	Proportion treated	Treatment	SVR rate	SVR (NS5A based)	SVR (PI based)
1a/1b			12/12 (100%)	2/2 (100%)	10/10 (100%)
1a and 1b	12/20	2 Sofosbuvir/ledipasvir 7 Paritaprevir/ritonavir/ombitasvir dasabuvir 3 Grazoprevir/elbasvir	2/2 7/7 3/3		
Distinct G1 subtypes			21/28 (75%)	9/15 (60%)	12/13 (92%)
1*	16/22	7 Sofosbuvir/ledipasvir 6 Paritaprevir/ritonavir/ombitasvir dasabuvir 3 Grazoprevir/elbasvir	5/7 6/6 2/3		
1e	2/4	1 Sofosbuvir/ledipasvir 1 Grazoprevir/elbasvir	1/1 1/1		
1g	5/5	3 Sofosbuvir/ledipasvir 1 Paritaprevir/ritonavir/ombitasvir dasabuvir 1 Grazoprevir/elbasvir	3/3 1/1 1/1		
1l	3/3	3 Sofosbuvir/ledipasvir	0/3		
1p	2/3	1 Sofosbuvir/ledipasvir 1 Paritaprevir/ritonavir/ombitasvir dasabuvir	0/1 1/1		
G4 subtypes			14/14 (100%)	2/2 (100%)	12/12 (100%)
Unknown 4	8/10	4 Paritaprevir/ritonavir/ombitasvir 4 Grazoprevir/elbasvir	8/8		
4e	3/4	1 Sofosbuvir/ledipasvir 1 Paritaprevir/ritonavir/ombitasvir, 1 Grazoprevir/elbasvir	3/3		
4f	2/3	1 Sofosbuvir/velpatasvir 1 Grazoprevir/elbasvir	2/2		
4k	1/2	1 Paritaprevir/ritonavir/ombitasvir	1/1		

PI, protease inhibitor; SVR, sustained virological response.

Factors associated with lack of SVR

A univariate categorical analysis was carried out to investigate which factors were associated with response. The presence of an unusual genotype 1 African subtype or the use of an NS5A inhibitor-based regimen were both significantly associated with a lack of SVR in univariate analysis, no other factors were. The results are shown in Table 3.

In multivariate analysis with SVR as the outcome variable, unusual genotype 1 remained highly significant with a *p* value of 0.016 (Chi-Squared: 5.78, *df* = 1), treatment regimen (NS5A inhibitor-based vs. protease inhibitor) was close to significant with a *p* value of 0.054 (Chi-Squared: 3.69, *df* = 1).

HCV sequence results

Baseline sequence data was available for 22 patients, 14 who achieved SVR, 6 treatment failures, 2 who have not yet been

treated. There were numerous NS5A polymorphisms present at baseline in patients with unusual G1 subtypes, particularly at positions 24, 30 and 31. Resistance-associated substitutions (RASs) listed in the EASL 2018 HCV guidelines as conferring reduced susceptibility to NS5A inhibitors or being associated with reduced treatment response were seen at baseline in 18/22 (82%) patients. All the treatment failures had either M28 polymorphisms (L and S) (2 failures) or L31M (4 failures). Five SVR patients had M28 (L and V), 3 patients (2 with 1* and 1 with 1g) who achieved SVR had Y93 (F/H/N) at baseline. These data are expanded in Table 4. The individual patient with 1* who has failed treatment with both sofosbuvir/ledipasvir and then glecaprevir/pibrentasvir had Q62E, L31M at baseline and Q62D, L31M following SOF/LDV. Following glecaprevir/pibrentasvir treatment Q30H, H58S and Y93H were also accumulated.

Discussion

In this analysis we report the prevalence of HCV genotypes in a consecutive cohort of 91 African patients from 18 countries, documenting the outcome of DAA therapy in patients with subtypes of genotype 1 and 4 that are prevalent in Africa but unusual in the West. Our study has 3 main findings. Firstly, unusual and previously undescribed subtypes were common. Secondly, there was a high degree of viral diversity and thirdly there was a lower SVR rate in those with unusual African subtypes, particularly in those who received a first generation NS5A inhibitor.

In this unselected cohort of immigrant African patients, 47 of 91 (52%) were infected by unusual African subtypes, (*i.e.* G1 non-1a/1b/ unassigned G1 subtype, or with G4 other than 4a or 4d). The distribution of genotypes was different from the non-African majority of our HCV patient cohort where G1a and 3a were the most common. The finding that unusual subtypes were common amongst African patients mirrors the

Table 3. Factors associated with achieving an SVR.

	SVR		<i>p</i> value by univariate analysis
	No	Yes	
Genotype			
Unusual G1	7	21	0.002
Any other genotype	0	35	
Treatment regimen			
NS5a	6	16	0.008
Protease inhibitor based	1	40	
Cirrhosis			
No	4	46	0.135
Yes	3	10	
Ribavirin use			
No	4	23	0.6
Yes	3	33	
HIV positive			
No	6	49	1.0
Yes	1	6	

SVR, sustained virological response.

Table 4. NS5A polymorphisms present at baseline and post treatment failure, where applicable.

SVR	Genotype	Baseline polymorphisms	Post-treatment RAS
No	1l	K24G, L31M , H58P	K24G , M28L, L31M , H58P,
No	1l	K24S, L31M , H58P,	K24S, L31M , H58P,
No	1l	K24G, Q30R, L31M , H58P	K24G, Q30R, L31M , H58P
No	1*	M28L, H58P, Q62D	M28F, H58P, Q62D ,
No	1p	M28S, Q30L , H58P, Q62P	M28S, Q30L , H58P, Q62D
No	1*	Q62E, L31M , H58P,	Q62D, L31M
Yes	1*	Q62D , H58P	n.a.
Yes	1g	K24R , M28L, H58P, Y93F	n.a.
Yes	1e	K24Q, M28L, Q30R, L31M , H58P, A92T	n.a.
Yes	1*	K24G , H58P	n.a.
Yes	1*	M28L, Q30L, L31M , H58P	n.a.
Yes	1*	M28V , H58P, Q62D	n.a.
Yes	1*	K24Q, Q62K, Y93H , H58P	n.a.
Yes	1*	S38A, H58P, Q62D	n.a.
Yes	1*	Q62E	n.a.
Yes	1*	M28V, Q30T , H58P, Y93N	n.a.
Yes	1*	H58P	n.a.
Yes	1*	K24Q, M28L, Q30L , H58P, Q62K, L31M	n.a.
Yes	1*	K24Q, M28L, Q30R , H58P,	n.a.
Yes	1*	H58P	n.a.
Untreated	1*	K24S, H58S,	n.a.
Untreated	1*	K24K, L31M H58P,	n.a.

G1 RASs as per 2018 EASL HCV Guidelines are in bold font. RAS, resistance-associated substitutions; SVR, sustained virological response.

results from the Los Alamos HCV database which contains 288 sequences of genotype 1c to 1m; 47.4% of these isolates originated in Africa.¹² The fact the majority of catalogued non-1a/b G1 subtypes originated in Africa and that the majority of our cohort were infected with unusual subtypes suggests that these subtypes are more common in Africa than Europe. Since 15% of global cases of HCV are based in the WHO African region,¹ these variants of HCV could be numerically significant. Population-based studies are required to establish the true prevalence of these “unusual” subtypes in Africa.

Our second finding was the high diversity of HCV sequences. We were able to sequence 15 previously undescribed subtypes of G1 HCV. One of these sequences was found to be a strain infecting 3 different patients, allowing formal classification as the novel genotype 1p. This is concordant with recent data from a cohort from Uganda and the Democratic Republic of Congo, where highly diverse genotype 4 and 7 strains, including unconfirmed novel strains were recently identified.² We can speculate that the diversity of HCV observed in this cohort and other studies, if confirmed by larger phylogenetic analyses, perhaps points to an early evolutionary origin of human hepatitis C genotype 1 and 4 in Africa.¹³

We observed a high number of resistance-associated polymorphisms in pre-treatment samples from our cohort. NS5A RASs listed in the 2018 EASL guidelines as conferring reduced susceptibility to NS5A inhibitors, for example at positions 24, 28, 30 and 31 were present in 82% of patients with baseline sequence data.¹⁴ This contrasts with published findings from the pooled analysis of phase II and III studies of sofosbuvir and ledipasvir; of 2,108 patients only 16% patients had detectable baseline RASs.¹⁵ That we saw such high frequencies of polymorphisms further demonstrates the diversity of the virus in the African region.

Our third finding was that SVR rates were markedly lower in this population. Although we have studied a relatively small number of patients, we show that the overall SVR rate for African patients at an experienced centre (89%), is lower than

expected in a group of predominantly non-cirrhotic patients. Importantly the SVR rate fell to 21/28 (75%), in those infected with non-1a/b G1 subtypes. The low SVR rate was driven by 6 failures in patients treated with sofosbuvir and ledipasvir, 1 failure with a protease inhibitor-based regimen and was associated with multiple baseline polymorphisms.

There is limited data available on treatment outcome in these uncommonly encountered genotypes. Zeuzem *et al.* have reported 25 patients with genotype 1 (1c/e/g/h/l) who all achieved SVR with an NS5a inhibitor-based regimen.⁸ These results were considered reassuring. It should be noted, however, that 18 patients received either sofosbuvir and velpatasvir, (7 with voxilaprevir) or 24 weeks of sofosbuvir and ledipasvir. Therefore, the majority of patients received the most potent treatment currently available, or else lengthened courses of treatment.

The French National Reference Centre recently reported that genotype 4r is associated with a lower response rate to DAAs. Five percent of all treatment failures were in patients infected with G4r, although this subtype is rare in the French population overall. Treatment failure was associated with multiple NS5A RASs which were present in all those analysed at baseline, similarly to our cohort.¹⁶ Gupta *et al.* recently published a large scale single arm trial in Rwanda showing that genotype 4r, present in 16% of participants, was associated with high rates of unsuccessful treatment with sofosbuvir and ledipasvir, despite good adherence.¹⁷ This has been linked to the presence of an amino acid motif, MPRMP, at positions 28-32 of the NS5A gene that confers high-level resistance to DAAs *in vitro*.¹⁸

Population-based studies to determine the frequency of unusual subtypes and the efficacy of DAA regimens against them, are urgently needed to formulate guidelines for treating HCV in Africa.¹⁹ The corollary of these data, and the fact that in resource poor regions of Africa genotyping or full genome sequencing will not be available, is that second generation NS5A inhibitors should be preferred as first-line agents in the region. Use of second-line NS5A inhibitors seems to overcome

resistance.²⁰ However further evaluation of the efficacy of newer regimens including sofosbuvir-velpatasvir or glecaprevir-pibrentasvir against the genotype 1 and 4 subtypes characterised in our analysis, is necessary. It has been suggested that a triple DAA regimen, including a protease inhibitor is required as first-line treatment.^{16,21}

We have shown that in a metropolitan United Kingdom cohort of African patients with HCV, most patients were infected with unusual and often novel African subtypes which were associated with reduced SVR rates. The reality of global migration means that these data are also relevant for clinicians in high income countries who should exercise caution in selecting regimens for African patients with unusual or unsubtypeable genotypes.

The evidence indicates that the future desired expansion of HCV treatment in Africa may risk unacceptable rates of failure if first generation NS5A inhibitors are utilised without appropriate epidemiological and viral sequence data. Global equity of access to curative treatment is required to avoid jeopardising the hepatitis C elimination agenda.

Financial support

This work was supported by the Medical Research Council (MRC) (MC_UU_12014/1) and Wellcome (102789/Z/13/A) both to Emma Thomson.

Conflict of interest

The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

Authors' contributions

Concept and design: K Childs, K Agarwal, M Cannon, G Dush-eiko. Data collection: K Childs, S Montague. Whole genome sequencing and analysis, review of manuscript: EC Thomson, C Davis, A da Silva Filipe, L Tong. Phylogenetic analysis: D Smith, P Simmonds. Writing of article: K Childs, M Cannon, G Dush-eiko, K Agarwal wrote the paper. All authors contributed to the preparation and review of the manuscript.

Acknowledgements

We wish to acknowledge the following individuals for their contributions to this study: M Bruce and M Horner, Institute of Liver Studies, King's College Hospital, D Childs, University of Sheffield. We thank all patients attending King's College Hospital Institute of Liver Studies.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.07.025>.

References

[1] Hutin Y. Global hepatitis report. World Health Organisation (WHO); 2017.

[2] Davis C, Sreenu VB, Young EH, Hughes J, Singer JB, Giroux G, et al. New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments. *Hepatology* 2018. <https://doi.org/10.1002/hep.30342>.

[3] Niebel M, Singer JB, Nickbakhsh S, Gifford RJ, Thomson EC. Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination? *Lancet Gastroenterol Hepatol* 2017. [https://doi.org/10.1016/S2468-1253\(17\)30257-1](https://doi.org/10.1016/S2468-1253(17)30257-1).

[4] Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. *Hepatology* 2014;59:318–327.

[5] Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. *J Hepatol* 2017;66:910–918. <https://doi.org/10.1016/j.jhep.2017.01.007>.

[6] HCV Sequence Database, Los Alamos HCV Database. Available at: <https://hcv.lanl.gov/components/sequence/HCV/geo/geo.comp>. Accessed: 1st May 2019.

[7] da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, et al. Reply to: Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. *J Hepatol* 2018;68:864–866. <https://doi.org/10.1016/j.jhep.2017.12>.

[8] Zeuzem S, Dvory-Sobol H, Brainard D. Reply to: Response to DAA therapy in the NHS England early access programme for rare HCV subtypes from low and middle income countries. *J Hepatol* 2017;67:1350–1352.

[9] Thomson E, Ip CLC, Badhan A, Christiansen MT, Adamson W, Ansari MA, et al. Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes. *J Clin Microbiol* 2016. <https://doi.org/10.1128/JCM.00330-16>.

[10] Firth D. Bias reduction of maximum likelihood. *Biometrika* 1993.

[11] Heinze G, Ploner M. logistf: Firth's Bias-Reduced Logistic Regression. R package version 1.23. (2018).

[12] Njouom R, Pepin J, Li C, Pybus OG, Nakano T, Bennett P, et al. Characterization of full-length hepatitis C virus sequences for subtypes 1e, 1h and 1l, and a novel variant revealed Cameroon as an area in origin for genotype 1. *J Gen Virol* 2013. <https://doi.org/10.1099/vir.0.048835-0>.

[13] Iles JC, Raghwanji J, Harrison GLA, Pepin J, Djoko CF, Tamoufe U, et al. Phylogeography and epidemic history of hepatitis C virus genotype 4 in Africa. *Virology* 2014. <https://doi.org/10.1016/j.virol.2014.07.006>.

[14] Pawlowsky J-M, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. EASL recommendations on treatment of hepatitis C 2018. *J Hepatol* 2018;69:461–511. <https://doi.org/10.1016/j.jhep.2018.03.026>.

[15] Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. *Gastroenterology* 2016;151:501–512.e1.

[16] Fourati S, Rodriguez C, Hézode C, Soulier A, Ruiz I, Poiteau L, et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. *Hepatology* 2019;69:513–523.

[17] Gupta N, Kabahizi J, Muvunyi C, Mbituyumuremyi A, Van Nuil J, Shumbusho F, et al. Direct-acting antiviral treatment in sub-Saharan Africa: a prospective trial of Ledipasvir/Sofosbuvir for chronic hepatitis C infection in Rwanda (the SHARED study). *J Hepatol* 2018. [https://doi.org/10.1016/s0168-8278\(18\)30320-9](https://doi.org/10.1016/s0168-8278(18)30320-9).

[18] Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, et al. Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1–4 in Italy. *Sci Rep* 2018. <https://doi.org/10.1038/s41598-018-26862-y>.

[19] Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C, Shafraan SD, et al. Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification. *Open Forum Infect Dis* 2019. <https://doi.org/10.1093/ofid/ofz076>.

[20] Camus G, Han B, Asselah T, Hsieh D, Dvory-Sobol H, Lu J, et al. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. *J Viral Hepatol* 2018;25:134–143.

[21] Han B, Parhy B, Zhou E, Hsieh D, Camus G, Martin R, et al. Susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangentotypic NS3/4A inhibitor voxilaprevir. *J Clin Microbiol* 2019;57:e01844–18.